Stock Taper
SCREENER COMPARE ANY 2 STOCKS
AVLN
AVALYN PHARMA INC. COMMON STOCK
NASDAQ
$34.69
▼ DOWN 4.98% (-1.82)

KEY STATISTICS

Market Cap$1.54 B
52w High$40.17
52w Low$24.15
Dividend Yield—
Frequency—
P/E-1.59
Volume202.89K
Shares Out.44.33M

COMPANY

LEADERSHIP

Lyn Baranowski
CHIEF EXECUTIVE
Lyn Baranowski

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 30, 2026
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
55

PRICE TARGET

Target High$80.00
Target Low$51.00
Target Median$54.50
Target Consensus$60.00

UPCOMING EARNINGS

DateSep 2, 2026
DayWednesday
Rev. Est.—
SEP
2
WED

PRICE

$34.69 ▼ DOWN 4.98% (−$1.82)
$34.50$35.25$36.00$36.759:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM34.69

About Avalyn Pharma Inc. Common Stock

http://www.avalynpharma.com ↗

Avalyn Pharma, Inc., a Boston-based clinical-stage biopharmaceutical company founded in 2011, develops inhaled medicines to treat rare respiratory diseases like pulmonary fibrosis and interstitial lung diseases.

INDUSTRY

Biotechnology

A PRODUCT AVALYN PHARMA INC. COMMON STOCK IS KNOWN FOR

AP01 (inhaled pirfenidone)
AP01 (inhaled pirfenidone)

AP01, Avalyn Pharma's inhaled pirfenidone candidate for progressive pulmonary fibrosis, is in Phase 2b trials, aiming to improve efficacy and reduce side effects by delivering medication directly to the lungs.

COMPETITORS

COMPETITOR
BMY COMPARE
INSM COMPARE
PLRX COMPARE
UTHR COMPARE
VRTX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
58
LISTED HERE
13
RANKED BY POSITION SIZE
VTI
0.00% · 534.4K
IWM
0.02% · 429.8K
SCHA
0.01% · 78.8K
TMSL
0.08% · 68.6K
R2US.L
0.01% · 21.6K
XRS2.F
0.02% · 16.5K
RSSL
0.02% · 8.2K
OMFS
0.03% · 2.4K
WCEO
0.58% · 2.2K
ETLZ.DE
0.03% · 1.9K
URTY
0.01% · 695
AVUS
0.00% · 447
RESM
0.05% · 76

INSTITUTIONAL OWNERSHIP

SHARES OWNED
65.67%
HOLDERS
75
TOP 12 OF 75 · RANKED BY POSITION SIZE
Fmr LLC
5.8M sh · $192.1M
Novo Holdings A/S
3.9M sh · $127.84M
Sr One Capital Management, LP
3.3M sh · $108.92M
Perceptive Advisors LLC
2.7M sh · $88.07M
Suvretta Capital Management, LLC
2.5M sh · $82.4M
Wellington Management Group Llp
2.2M sh · $72.49M
Price T Rowe Associates Inc /Md/
1.7M sh · $57.12M
Catalio Capital Management, LP
1.7M sh · $55.17M
T. Rowe Price Investment Management, Inc.
1.6M sh · $52.76M
Eventide Asset Management, LLC
1.4M sh · $45.28M
Bellevue Group AG
1.4M sh · $44.44M
Pivotal Bioventure Partners Investment Advisor LLC
966.8K sh · $31.83M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OVERWEIGHT 1
1 GRADES IN THE LAST 12 MONTHS
Morgan Stanley OVERWEIGHT